ohnson & Johnson has been actively engaged in fighting pandemics for over a century. We have done it before, and we will do it again.
With our global reach comes a responsibility and unique ability to leverage our deep scientific expertise and extensive partnerships to take on this challenge. Our more than 130,000 employees around the world are mobilizing with urgency to address the critical needs of families, communities and healthcare providers around the world.
Our commitment to families around the world doesn’t change in a time of crisis: we’ll never stop taking care of you.
China alerted the World Health Organization (WHO) to several cases of pneumonia in Wuhan. The virus is unknown.
WHO announces they have identified a new virus named 2019-nCoV, also known as Wuhan coronavirus. It is from the CoV family, which includes SARS and the common cold.
First death linked to 2019-nCoV.
J&J initiates efforts to develop a vaccine candidate against 2019-nCoV and to broadly collaborate with others to screen a library of antiviral molecules.
WHO declares the 2019-nCoV outbreak a public health emergency of international concern (PHEIC).
First death linked to 2019-nCoV was reported outside of China, in the Philippines.
COVID-19 is announced as the official name of the disease caused by novel coronavirus. The virus is named SARS-CoV-2.
J&J announces collaboration with U.S. Department of Health & Human Services to accelerate development of a potential COVID-19 vaccine.
J&J announces expanded collaboration with U.S. Department of Health & Human Services to accelerate discovery of potential COVID-19 treatments.
Europe has its first major outbreak of COVID-19, in the Lombardy region of northern Italy
The first case of COVID-19 was reported in South America, marking the spread of the disease to six of seven continents.
WHO declares the COVID-19 outbreak a pandemic.
J&J announces a $50 million commitment to support frontline health workers battling COVID-19.
J&J announces a lead vaccine candidate will move into trials and pledges to supply 1B vaccines worldwide for emergency pandemic use. BARDA and J&J commit $1B to vaccine R&D.
J&J enters into a collaboration with Emergent BioSolutions, Inc., to support the manufacturing of its lead investigational COVID-19 vaccine candidate.
J&J announces acceleration of its COVID-19 vaccine candidate: Phase 1/2a clinical trial to begin in second half of July.